Baxter announced Thursday morning it will split into two companies, separating its $6 billion biopharma operation from its $9 billion medical device and diagnostics business. The company is also looking into selling its vaccine business, Reuters reported Wednesday. The process is at an early stage, with Baxter having recently tapped Goldman Sachs to advise and begun contacting potential buyers, including private equity firms. Sales of vaccines against meningitis C and tick-borne encephalitis helped the business bring in $300 million last year. The unit is profitable, but Baxter reportedly considers it noncore. Novartis ($NVS) is also thinking of selling its vaccine unit. Article | More from FierceBiotech